3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
20
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Neoplasms
4
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Merkel Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Cutaneous
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Mesothelioma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
3
poly ICLC
1
osimertinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
cobimetinib
1
atezolizumab
1
advexin
1
Taxes
1
Risk Factors
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Injections, Subcutaneous
1
High-Intensity Focused Ultrasound Ablation
1
Gemcitabine
1
Fluorouracil
1
Dimethyl Sulfoxide
1
Cyclophosphamide
1
Cisplatin
1
Ascorbic Acid
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
poly ICLC
×
Dermatologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled